Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rAAVrh74.MCK.GALGT2 Gene Transfer for Duchenne Muscular Dystrophy
NCT02704325Phase 2Withdrawn
- Sponsor
- Kevin Flanigan (Nationwide Children's Hospital)
- Start
- Apr 2016
- Primary completion
- Jul 2018
- Modality
- Gene Editing, Gene Silencing, Viral Vectors
- Countries
- 1
01
Overview
A Phase 2 trial of rAAVrh74.MCK.GALGT2 in Duchenne muscular dystrophy (DMD), sponsored by Kevin Flanigan (Nationwide Children's Hospital). Planned start Apr 2016; status: withdrawn.
02
Drugs
rAAVrh74.MCK.GALGT2
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT02704325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02704325.